Pemigatinib plus durvalumab for advanced bile duct cancer
Part of Cancer clinical trials.
This trial tests a combination of two drugs, pemigatinib and durvalumab, for people whose advanced bile duct or gallbladder cancer has already been treated once. It aims to see if the combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and your daily activities are not limited by the cancer (ECOG 0-1).
- You have already had one type of treatment for your advanced gallbladder cancer or cholangiocarcinoma (bile duct cancer).
- Your tumor has a specific gene change called FGFR2 fusion or rearrangement (found through a biopsy).
- You have at least one tumor that can be measured on a CT or MRI and has not been treated with radiation.
- Your blood counts, liver and kidney function, and heart are working well enough (confirmed by tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—durvalumab (an immunotherapy) and olaparib (a targeted therapy)—for people with advanced bile duct cancer that did not grow after initial treatment with chemotherapy and durvalumab. The goal is to see if this combination can help control the cancer further.
This study tests whether combining two immunotherapy drugs—pucotenlimab (a PD-1 inhibitor that boosts your immune system) and becotatugvedotin (an antibody-drug that targets EGFR cancer cells)—can shrink advanced cholangiocarcinoma (bile duct or gallbladder cancer). The goal is to see if this combination works better and is safe for patients whose cancer cannot be surgically removed or has spread.
This trial tests a combination of radiation therapy (PULSAR), immunotherapy, and chemotherapy for advanced bile duct cancer. It aims to see if this approach can shrink tumors and improve survival.
This trial tests a combination of chemotherapy, immunotherapy, and heat therapy (hyperthermia) with a special radiation technique for advanced bile duct or gallbladder cancer that hasn't been treated before. It aims to see if this combination can help shrink tumors and improve outcomes.
This trial tests combining immunotherapy (anti-PD-1/PD-L1 antibodies) with standard chemotherapy (gemcitabine and cisplatin) for people with advanced bile duct or gallbladder cancer that can't be removed by surgery. The goal is to see if this combination works better than chemo alone.
This trial tests a combination of two drugs, pemigatinib and durvalumab, in people with a certain type of advanced bile duct cancer that has a specific genetic change (FGFR2 fusion or rearrangement). The goal is to see if this combination can help when standard treatments have stopped working.
Hear when a new Biliary Tract Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.